Yahoo
NasdaqCM - Nasdaq Real Time Price USD

ABVC BioPharma, Inc. (ABVC)

1.0400 +0.0400 (+3.98%)
As of 9:56:02 AM EST. Market Open.
Chart Range Bar
Loading chart for ABVC
  • Previous Close 1.0000
  • Open 1.0100
  • Bid 1.0400 x 100
  • Ask 1.3100 x 200
  • Day's Range 1.0001 - 1.0499
  • 52 Week Range 0.7070 - 3.0600
  • Volume 6,069
  • Avg. Volume 100,240
  • Market Cap (intraday) 27.762M
  • Beta (5Y Monthly) 0.50
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3000
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.

www.abvcpharma.com

16

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ABVC
51.17%
S&P 500 (^GSPC)
11.39%

1-Year Return

ABVC
62.86%
S&P 500 (^GSPC)
11.47%

3-Year Return

ABVC
13.33%
S&P 500 (^GSPC)
76.59%

5-Year Return

ABVC
97.66%
S&P 500 (^GSPC)
64.66%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY23
Revenue 128.27k
Earnings --
Profit Margin 0.00%

Q2

FY22

Q3

FY22

Q4

FY22

Q1

FY23

-4M
-3M
-2M
-1M
0
-8000.0%
-6000.0%
-4000.0%
-2000.0%
0.0%

Statistics

View More

Valuation Measures

Annual
As of 10/30/2026
  • Market Cap

    26.69M

  • Enterprise Value

    31.20M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    31.28

  • Price/Book (mrq)

    2.43

  • Enterprise Value/Revenue

    39.20

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -22.85%

  • Return on Equity (ttm)

    -69.86%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -7.11M

  • Diluted EPS (ttm)

    -0.3000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    94.36k

  • Total Debt/Equity (mrq)

    23.53%

  • Levered Free Cash Flow (ttm)

    1.56M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.0400 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: